Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid TumorsByBob T. Li, MD, PhD, MPHJune 13th 2023Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.